Costs of stroke in Sweden. A national perspective.

Abstract

Background and Purpose Cost-effectiveness analyses of stroke management are hampered by paucity of economic data. We made an update of the direct and indirect costs of stroke in Sweden (population, 8.5 million).Methods Direct costs (ie, the costs for hospital and outpatient care and social services) were estimated on the basis of two prospective population-based studies of stroke and of two nationwide cross-sectional inventories of bed-days and diagnoses. Indirect costs (ie, the costs for loss of productivity and early retirement) were based on official statistics.Results The direct annual costs of care for stroke patients in 1991 equaled 7836 million Swedish krona (SKr) ($1306 million in US dollars), and the indirect costs, 2430 million SKr

Does a short period of rehabilitation in the home setting facilitate functioning after stroke? A randomized controlled trial

“…Several studies have investigated the incidence / prevalence and cost of stroke (Truelsen et al 2005) (Ghatnekar et al 2004) (Ghatnekar et al 2004) (Grieve et al 2000) (Claesson et al 2000) and the long term cost of illness in stroke patients (Payne et al 2002) (Evers et al 1997) (Terent et al 1994). The demand for studies of cost of stroke will continue to increase over the coming years as a result of the high prevalence of stroke and the frequent long term consequences of survivors' disabilities, which represent a substantial socioeconomic burden associated with the disease.…”

Cost of Stroke in Australia From a Societal Perspective

“…9,12 A number of cost-of-illness (COI) studies for stroke have been conducted by means of an incidence-based approach. 4,7,10,[13][14][15] The incidence-based approach estimates the present value of the lifetime costs for all new (incident) cases occurring during a given reference year, even though many costs will actually be incurred during future years. This is the method of choice if the consequences of preventative and treatment strategies are to be appreciated in terms of their effects on lifetime costs and options for change evaluated in terms of their economic efficiency.…”

Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study

“…The lifetime direct medical costs of managing stroke were based on the STEM estimate of d48 345 (1996 costs), 14 consistent with lifetime direct medical costs for stroke reported for other European countries, such as $73 333 in Sweden (1991 costs) 16 and $41 284 in the Netherlands (1991 costs). 17 For the purpose of this analysis, costs were inflated from 1996 (d48 345 (h70 100)) to 2003 values (d60 431 (h87 625)) using the consumer price index for health.…”

“…8 However, although the costs associated with acute care have been widely reported, [9][10][11] relatively few studies have evaluated the long-term costs of stroke management. [12][13][14][15][16][17] As stroke is a disease of the elderly, with an increasingly ageing population 18 it is anticipated that the incidence of stroke and associated demands on healthcare costs will rise substantially in the future. However, as healthcare funds are limited, cost-effective stroke prevention strategies are clearly needed.…”